ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...

MPP执行董事Charles Gore指出，该组织此前与ViiV就多替拉韦达成的协议已使129个国家能够获得基于DTG的仿制HIV治疗药物，他补充说，他们希望"CAB LA能够实现类似的覆盖范围"。想要深入了解葛兰素史克的财务健康状况和增长潜力？ InvestingPro 订阅者可以获取超过30项额外的财务指标和专家分析，包括独家ProTips和全面的研究报告。

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

No investor will be happy with their GSK shares as the FTSE 100 pharmaceutical giant has had a dismal decade. Will the next ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, ...